Trial Outcomes & Findings for Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate (NCT NCT03659929)

NCT ID: NCT03659929

Last Updated: 2024-09-03

Results Overview

Change from baseline in severity of Attention Deficit Hyperactivity (ADHD) symptoms, as measured by the adult ADHD Investigator Symptom Rating Scale (AISRS), with a minimum score of 0, and maximum score of 54. Higher scores indicate more severe symptoms, or a worse outcome.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

320 participants

Primary outcome timeframe

Week 5 (Visit 7)

Results posted on

2024-09-03

Participant Flow

Participant milestones

Participant milestones
Measure
Placebo
Placebo, no active drug Placebo: Matching placebo
Amphetamine Sulfate (20 mg/Day)
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Amphetamine Sulfate (40 mg/Day)
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Overall Study
STARTED
106
107
107
Overall Study
COMPLETED
92
87
87
Overall Study
NOT COMPLETED
14
20
20

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Placebo
n=106 Participants
Placebo, no active drug Placebo: Matching placebo
Amphetamine Sulfate (20 mg/Day)
n=107 Participants
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Amphetamine Sulfate (40 mg/Day)
n=107 Participants
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Total
n=320 Participants
Total of all reporting groups
Age, Continuous
34.2 years
STANDARD_DEVIATION 10.75 • n=99 Participants
35.6 years
STANDARD_DEVIATION 10.28 • n=107 Participants
33.5 years
STANDARD_DEVIATION 9.35 • n=206 Participants
34.4 years
STANDARD_DEVIATION 10.15 • n=7 Participants
Sex: Female, Male
Female
52 Participants
n=99 Participants
50 Participants
n=107 Participants
44 Participants
n=206 Participants
146 Participants
n=7 Participants
Sex: Female, Male
Male
54 Participants
n=99 Participants
57 Participants
n=107 Participants
63 Participants
n=206 Participants
174 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
14 Participants
n=99 Participants
13 Participants
n=107 Participants
14 Participants
n=206 Participants
41 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
92 Participants
n=99 Participants
94 Participants
n=107 Participants
93 Participants
n=206 Participants
279 Participants
n=7 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
1 Participants
n=7 Participants
Race (NIH/OMB)
Asian
6 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
9 Participants
n=7 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
1 Participants
n=7 Participants
Race (NIH/OMB)
Black or African American
13 Participants
n=99 Participants
13 Participants
n=107 Participants
15 Participants
n=206 Participants
41 Participants
n=7 Participants
Race (NIH/OMB)
White
80 Participants
n=99 Participants
89 Participants
n=107 Participants
88 Participants
n=206 Participants
257 Participants
n=7 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Unknown or Not Reported
6 Participants
n=99 Participants
4 Participants
n=107 Participants
1 Participants
n=206 Participants
11 Participants
n=7 Participants
ADHD Type
Inattentive
14 Participants
n=99 Participants
19 Participants
n=107 Participants
20 Participants
n=206 Participants
53 Participants
n=7 Participants
ADHD Type
Hyperactive/Impulsive
1 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
1 Participants
n=7 Participants
ADHD Type
Combined
91 Participants
n=99 Participants
88 Participants
n=107 Participants
87 Participants
n=206 Participants
266 Participants
n=7 Participants

PRIMARY outcome

Timeframe: Week 5 (Visit 7)

Change from baseline in severity of Attention Deficit Hyperactivity (ADHD) symptoms, as measured by the adult ADHD Investigator Symptom Rating Scale (AISRS), with a minimum score of 0, and maximum score of 54. Higher scores indicate more severe symptoms, or a worse outcome.

Outcome measures

Outcome measures
Measure
Placebo
n=103 Participants
Placebo, no active drug Placebo: Matching placebo
Amphetamine Sulfate (20 mg/Day)
n=106 Participants
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Amphetamine Sulfate (40 mg/Day)
n=105 Participants
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Change From Baseline in Severity of Attention Deficit Hyperactivity (ADHD) Symptoms
-11.1 score on a scale
Standard Error 1.28
-18.2 score on a scale
Standard Error 1.28
-18.1 score on a scale
Standard Error 1.27

SECONDARY outcome

Timeframe: Up to 5 weeks

Items are scored as follows: 0 (none), 1 (mild), 2 (moderate), 3 (severe). The maximum total score for the scale is 54 points, with 27 points for each subscale (summed). The total score is the sum of the inattentive and hyperactive-impulsive subscales. Higher values represent more severe hyperactivity and/or inattentiveness.

Outcome measures

Outcome measures
Measure
Placebo
n=103 Participants
Placebo, no active drug Placebo: Matching placebo
Amphetamine Sulfate (20 mg/Day)
n=106 Participants
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Amphetamine Sulfate (40 mg/Day)
n=105 Participants
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Change From Baseline to Visit 7 in AISRS Hyperactive and Inattentive Subscale Scores
Hyperactivity/Impulsivity Subscale
-5.2 score on a scale
Standard Error 0.61
-8.3 score on a scale
Standard Error 0.61
-8.0 score on a scale
Standard Error 0.6
Change From Baseline to Visit 7 in AISRS Hyperactive and Inattentive Subscale Scores
Inattentive Subscale
-5.9 score on a scale
Standard Error 0.74
-9.9 score on a scale
Standard Error 0.74
-10.0 score on a scale
Standard Error 0.74

SECONDARY outcome

Timeframe: Up to 5 weeks

CGI-Severity (CGI-S): The CGI-Severity (CGI-S) asks the clinician one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.

Outcome measures

Outcome measures
Measure
Placebo
n=103 Participants
Placebo, no active drug Placebo: Matching placebo
Amphetamine Sulfate (20 mg/Day)
n=106 Participants
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Amphetamine Sulfate (40 mg/Day)
n=105 Participants
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Change in Clinical Global Impression of Severity (CGI-S) Score From Baseline
Visit 3 (Week 1)
-0.5 score on a scale
Standard Error 0.1
-0.9 score on a scale
Standard Error 0.1
-1.0 score on a scale
Standard Error 0.1
Change in Clinical Global Impression of Severity (CGI-S) Score From Baseline
Visit 4 (Week 2)
-0.7 score on a scale
Standard Error 0.12
-1.1 score on a scale
Standard Error 0.12
-1.3 score on a scale
Standard Error 0.12
Change in Clinical Global Impression of Severity (CGI-S) Score From Baseline
Visit 5 (Week 3)
-0.8 score on a scale
Standard Error 0.12
-1.4 score on a scale
Standard Error 0.12
-1.5 score on a scale
Standard Error 0.12
Change in Clinical Global Impression of Severity (CGI-S) Score From Baseline
Visit 6 (Week 4)
-0.8 score on a scale
Standard Error .12
-1.4 score on a scale
Standard Error .12
-1.5 score on a scale
Standard Error 0.12
Change in Clinical Global Impression of Severity (CGI-S) Score From Baseline
Visit 7 (End of Study/End of Treatment)
-0.9 score on a scale
Standard Error .13
-1.5 score on a scale
Standard Error .13
-1.5 score on a scale
Standard Error .13

SECONDARY outcome

Timeframe: Up to 5 weeks

"Compared to the patient's condition at admission to the project \[prior to medication initiation\], this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment."

Outcome measures

Outcome measures
Measure
Placebo
n=103 Participants
Placebo, no active drug Placebo: Matching placebo
Amphetamine Sulfate (20 mg/Day)
n=106 Participants
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Amphetamine Sulfate (40 mg/Day)
n=105 Participants
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Change in Clinical Global Impression of Improvement (CGI-I) Score From Baseline
Visit 7 (End of Study/End of Treatment)
3.1 score on a scale
Standard Error 0.12
2.5 score on a scale
Standard Error 0.12
2.4 score on a scale
Standard Error 0.12
Change in Clinical Global Impression of Improvement (CGI-I) Score From Baseline
Visit 3 (Week 1)
3.3 score on a scale
Standard Error 0.1
2.9 score on a scale
Standard Error 0.1
2.8 score on a scale
Standard Error 0.1
Change in Clinical Global Impression of Improvement (CGI-I) Score From Baseline
Visit 4 (Week 2)
3.2 score on a scale
Standard Error 0.11
2.6 score on a scale
Standard Error 0.11
2.4 score on a scale
Standard Error 0.11
Change in Clinical Global Impression of Improvement (CGI-I) Score From Baseline
Visit 5 (Week 3)
3.0 score on a scale
Standard Error 0.11
2.6 score on a scale
Standard Error 0.11
2.4 score on a scale
Standard Error 0.11
Change in Clinical Global Impression of Improvement (CGI-I) Score From Baseline
Visit 6 (Week 4)
3.1 score on a scale
Standard Error 0.11
2.5 score on a scale
Standard Error 0.11
2.4 score on a scale
Standard Error 0.11

SECONDARY outcome

Timeframe: Up to 5 weeks

The Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) is a 75-item self-rating scale that assesses overall functioning (GEC) and 9 non-overlapping scales among 2 summary index scales (Metacognition Index \[MI\] and Behavioral Regulation Index \[BRI\]) that assess aspects of executive function and problems with self-regulation from the perspective of the individual. Subjects rate each item on a 3-point scale (1=Never, 2=Sometimes, or 3=Often) based on their experience in past month. The sum of 70 items yields the GEC raw score (range: 70-210), which is converted to a T-score (normative population mean=50 and standard deviation=10; T-score ≥ 65 is considered abnormally elevated). The post-baseline GEC T-score is converted to a change from baseline T-score. A lower change from baseline GEC T-score (\<0) represents a better outcome.

Outcome measures

Outcome measures
Measure
Placebo
n=103 Participants
Placebo, no active drug Placebo: Matching placebo
Amphetamine Sulfate (20 mg/Day)
n=106 Participants
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Amphetamine Sulfate (40 mg/Day)
n=105 Participants
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Global Executive Composite T-Score
-7.4 T-Score
Standard Error 1.33
-13.6 T-Score
Standard Error 1.35
-14.6 T-Score
Standard Error 1.31
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Behavioral Regulation Index T-Score
-6.4 T-Score
Standard Error 1.15
-11.5 T-Score
Standard Error 1.17
-12.8 T-Score
Standard Error 1.14
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Metacognition Index (MI) T-Score
-7.2 T-Score
Standard Error 1.32
-13.4 T-Score
Standard Error 1.37
-14.2 T-Score
Standard Error 1.33
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Inhibit T-Score
-7.1 T-Score
Standard Error 1.22
-11.3 T-Score
Standard Error 1.25
-13.0 T-Score
Standard Error 1.21
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Self-Monitor T-Score
-5.2 T-Score
Standard Error 1.10
-10.6 T-Score
Standard Error 1.12
-11.9 T-Score
Standard Error 1.09
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Plan/Organize T-Score
-6.9 T-Score
Standard Error 1.30
-12.2 T-Score
Standard Error 1.33
-12.9 T-Score
Standard Error 1.29
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Shift T-Score
-4.8 T-Score
Standard Error 1.13
-9.8 T-Score
Standard Error 1.16
-10.4 T-Score
Standard Error 1.13
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Initiate T-Score
-5.0 T-Score
Standard Error 1.16
-10.3 T-Score
Standard Error 1.19
-11.2 T-Score
Standard Error 1.15
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Task Monitor T-Score
-6.8 T-Score
Standard Error 1.33
-12.6 T-Score
Standard Error 1.36
-13.5 T-Score
Standard Error 1.32
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Emotional Control T-Score
-3.9 T-Score
Standard Error 0.94
-7.1 T-Score
Standard Error 0.96
-8.0 T-Score
Standard Error 0.93
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Working Memory T-Score
-7.5 T-Score
Standard Error 1.36
-13.4 T-Score
Standard Error 1.40
-14.8 T-Score
Standard Error 1.36
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
Organization of Materials T-Score
-4.3 T-Score
Standard Error 1.09
-9.5 T-Score
Standard Error 1.12
-10.0 T-Score
Standard Error 1.09

Adverse Events

Placebo

Serious events: 0 serious events
Other events: 19 other events
Deaths: 0 deaths

Amphetamine Sulfate (20 mg/Day)

Serious events: 0 serious events
Other events: 46 other events
Deaths: 0 deaths

Amphetamine Sulfate (40 mg/Day)

Serious events: 0 serious events
Other events: 55 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Placebo
n=106 participants at risk
Placebo, no active drug Placebo: Matching placebo
Amphetamine Sulfate (20 mg/Day)
n=107 participants at risk
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Amphetamine Sulfate (40 mg/Day)
n=107 participants at risk
Amphetamine Sulfate Amphetamine Sulfate: active experimental AR19
Psychiatric disorders
Insomnia
3.8%
4/106 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
8.4%
9/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
9.3%
10/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
Gastrointestinal disorders
Dry Mouth
3.8%
4/106 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
5.6%
6/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
11.2%
12/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
Nervous system disorders
Headache
12.3%
13/106 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
13.1%
14/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
11.2%
12/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
Infections and infestations
Nasopharyngitis
5.7%
6/106 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
4.7%
5/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
2.8%
3/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
Metabolism and nutrition disorders
Decreased Appetite
4.7%
5/106 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
10.3%
11/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
13.1%
14/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
Cardiac disorders
Palpitations
1.9%
2/106 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
1.9%
2/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
6.5%
7/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
Cardiac disorders
Tachycardia
0.00%
0/106 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
5.6%
6/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])
3.7%
4/107 • Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5])

Additional Information

Vice President of Clinical Development

Azurity Pharmaceuticals, Inc.

Phone: 1-800-461-7449

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place